)
Visual
test
Corline Biomedical
Corline Biomedical (CLBIO) investor relations material
Corline Biomedical Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary18 Nov, 2025
Executive summary
Achieved a breakthrough period with FDA approval for a partner's product using CHSTM technology and a 10-year license and supply agreement with Kardium.
Raised 23 MSEK through a directed share issue to Eiffel Investment Group to support expansion, especially in the US.
Focused on scaling production and ensuring quality to meet anticipated demand from Kardium and future customers.
Financial highlights
Net sales for Q3 2025 were 1,305 KSEK, down from 1,770 KSEK in Q3 2024; for Jan–Sep 2025, net sales were 5,547 KSEK, down from 7,763 KSEK year-over-year.
Result after financial items for Q3 2025 was -3,359 KSEK (Q3 2024: -2,996 KSEK); Jan–Sep 2025: -9,687 KSEK (Jan–Sep 2024: -9,033 KSEK).
Earnings per share for Q3 2025 were -0.14 SEK (unchanged year-over-year); Jan–Sep 2025: -0.40 SEK (-0.42 SEK year-over-year).
Cash and cash equivalents at September 30, 2025, were 5.8 MSEK (7.3 MSEK year-over-year).
Equity at period end was 77,227 KSEK (84,506 KSEK year-over-year); equity ratio 94% (91%).
Outlook and guidance
Anticipates increased revenues and financial stability from the long-term Kardium agreement and new capital injection.
Plans to expand the customer base in the US and Europe, reducing dependency on a single client.
Detailed commercial expansion plan for the US to be presented in Q1 2026.
How will CHS™ production scale for Kardium?
US market entry plan for CHS™ Growth Initiative?
Kardium minimum volumes: financial impact?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 5 FebDG
Record free cash flow and broad-based earnings growth drive strong 2025 results and positive 2026 outlook. - 5 FebMOD
Q3 FY26 sales up 31%, strong data center growth, pension charge led to net loss, major spin-off announced. - 5 FebAPOLLOTYRE
Record revenue, profit growth, major expansion, and improved financial metrics in Q3 FY26. - 5 FebCMI
Record 2025 results, $458M Accelera charges, and 2026 growth led by data center power. - 5 FebHP
EBITDA $230M, $1.02B revenue, net loss $97M, $260M debt repaid, strong tech rollout. - 5 FebNOV
Q4 2025 revenue up 5% sequentially, strong cash flow, 2026 outlook cautious but improving. - 5 FebGL
Earnings and premium growth drive strong results, higher 2026 guidance, and ongoing share buybacks. - 5 FebRRX
Q4 orders up 53.8% with $735M E-Pod win; 2026 EPS guidance up ~10%. - 5 FebSNA
Q4 sales up 2.8%, EPS at $4.94, strong cash, and a notable building sale gain. - 5 FebRBC
Q3 sales rose 17% with strong A&D growth, high cash flow, and record $2.1B backlog.
Next Corline Biomedical earnings date
Q4 202517 Feb, 2026
Corline Biomedical
Next Corline Biomedical earnings date
Q4 202517 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Corline Biomedical AB is a Swedish biotechnology company focused on developing heparin-based medical solutions to improve outcomes in kidney transplantation and cell therapies. The company’s proprietary Corline Heparin Conjugate (CHC) technology is central to its product offerings. Key products include Renaparin, aimed at improving kidney transplantation by reducing complications during surgery, and Cytoparin, designed for cell therapy applications, particularly in the treatment of type 1 diabetes. The company is headquartered in Uppsala, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage